Welcome to our dedicated page for Kura Oncology news (Ticker: $KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kura Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kura Oncology's position in the market.
Kura Oncology, Inc. announced the granting of inducement awards in the form of nonstatutory stock options to six new employees under the 2023 Inducement Option Plan. The stock options will allow the purchase of 67,950 shares of common stock at an exercise price of $20.28 per share. The options will vest over four years, with 25% vesting after one year, and the rest vesting monthly over 36 months, contingent on the employees' continued service relationship.
Kura Oncology reported first quarter 2024 financial results, highlighting Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML, positive preliminary combination data, and first patient dosing with KO-2806 and cabozantinib. The company has $527 million in cash, cash equivalents, and investments, ensuring runway into 2027. Financially, research and development expenses increased to $36.3 million, while general and administrative expenses rose to $18.2 million. The net loss for Q1 2024 was $49.5 million. Management expects current funds to last into 2027.
